HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (23) Citing Articles via Google Scholar Google Scholar Articles by Abbasi, F. Articles by Reaven, P. D. Search for Related Content PubMed PubMed Citation Articles by Abbasi, F. Articles by Reaven, P. D.

CALL FOR PAPERS
Metabolic Syndrome

Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes

¹Department of Medicine, Stanford University School of Medicine, Stanford; ²Medical Research Service, Veterans Affairs San Diego Healthcare System and Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, California; and ³Medical Research Service, Division of Endocrinology and Metabolism, Department of Medicine, Carl T. Hayden Veterans Affairs Medical Center, Phoenix, Arizona

Submitted 22 April 2005 ; accepted in final form 30 August 2005

It has been suggested that changes in adiponectin levels may contribute to improved insulin sensitivity in insulin-resistant individuals both after weight loss and after treatment with thiazolidinedione compounds. If this is correct, then changes in total circulating adiponectin and/or distribution of its multimeric complexes should coincide with improvements in insulin sensitivity after both interventions. To address this issue, fasting adiponectin concentrations and distribution of adiponectin complexes were measured in plasma samples in 24 insulin-resistant, nondiabetic subjects before and after 3–4 mo of treatment with either rosiglitazone or caloric restriction. The degree of insulin resistance in each group of 12 subjects was equal at baseline and improved to a similar extent (30%) after each therapy. Whereas total adiponectin levels increased by nearly threefold and the relative amount of several higher molecular weight adiponectin complexes increased significantly in the rosiglitazone treatment group, there were no discernible changes in adiponectin levels or in the distribution between high or low molecular weight complexes in the weight loss group. These data indicate that, although changes in total adiponectin and several specific adiponectin complexes paralleled improvements in insulin resistance in thiazolidinedione-treated subjects, neither circulating adiponectin concentrations nor multimeric complexes changed in association with enhanced insulin sensitivity after moderate weight loss in 12 insulin-resistant, obese individuals.

thiazolidinedione; adiponectin multimers; high molecular weight complexes

This article has been cited by other articles:

				T. P. J. Solomon, S. N. Sistrun, R. K. Krishnan, L. F. Del Aguila, C. M. Marchetti, S. M. O'Carroll, V. B. O'Leary, and J. P. Kirwan Exercise and diet enhance fat oxidation and reduce insulin resistance in older obese adults J Appl Physiol, May 1, 2008; 104(5): 1313 - 1319. [Abstract] [Full Text] [PDF]

				M. Martin, L. P. Palaniappan, A. C. Kwan, G. M. Reaven, and P. D. Reaven Ethnic Differences in the Relationship Between Adiponectin and Insulin Sensitivity in South Asian and Caucasian Women Diabetes Care, April 1, 2008; 31(4): 798 - 801. [Abstract] [Full Text] [PDF]

				J. B Keogh, G. D Brinkworth, M. Noakes, D. P Belobrajdic, J. D Buckley, and P. M Clifton Effects of weight loss from a very-low-carbohydrate diet on endothelial function and markers of cardiovascular disease risk in subjects with abdominal obesity Am. J. Clinical Nutrition, March 1, 2008; 87(3): 567 - 576. [Abstract] [Full Text] [PDF]

				E. Corpeleijn, E. J.M. Feskens, E. H.J.M. Jansen, M. Mensink, W. H.M. Saris, and E. E. Blaak Lifestyle Intervention and Adipokine Levels in Subjects at High Risk for Type 2 Diabetes: The Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM) Diabetes Care, December 1, 2007; 30(12): 3125 - 3127. [Abstract] [Full Text] [PDF]

				V. B. O'Leary, A. E. Jorett, C. M. Marchetti, F. Gonzalez, S. A. Phillips, T. P. Ciaraldi, and J. P. Kirwan Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E421 - E427. [Abstract] [Full Text] [PDF]

				R. Belfort, S. A. Harrison, K. Brown, C. Darland, J. Finch, J. Hardies, B. Balas, A. Gastaldelli, F. Tio, J. Pulcini, et al. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis N. Engl. J. Med., November 30, 2006; 355(22): 2297 - 2307. [Abstract] [Full Text] [PDF]